Economic evaluation of tislelizumab versus chemotherapy as second-line treatment for advanced or metastatic esophageal squamous cell carcinoma in China

Overview of attention for article published in Frontiers in Pharmacology, November 2022

Altmetric Badge

Mentioned by

twitter: 1 X user

Readers on

mendeley: 1 Mendeley

So far, Altmetric has seen 1 X post from an account with 5,739 followers.

New Research: Economic evaluation of tislelizumab versus chemotherapy as second-line treatment for advanced or metastatic esophageal squamous cell carcinoma in China https://t.co/FMIJwjmuOG #pharmacology

16 Nov 2022

Reply Repost Favourite

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity.